Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
How Information is Consumed
Summary
In this episode, Tom Caravela is joined by Andrew Fariello from AstraZeneca to explore the evolving landscape of Medical Science Liaisons (MSLs) in the context of data sharing and technological advancements. Andrew shares his career journey and insights into the growing importance of surveillance networks and real-world data, especially following the pandemic. The discussion delves into adapting MSL strategies to handle information overload while integrating patient perspectives into medical strategies. Andrew emphasizes the critical role of MSLs, highlighting advancements in engagement and innovative tools. The episode concludes with advice for MSLs navigating scientific developments and a call to action for listeners.
Today’s guest is Andrew Fariello, VP Global Medical Affairs, Head Medical Excellence, Oncology who discusses trends in information/data consumption and what MSLs can do for greater impact
We learn….
π How data is being shared as well as how it is being consumed
π What he means by the term “instantaneous Information”
π What role MSLs play in patient care and patient identification
π How the MSL approach may need to change
π Areas of improvement for MSLs in KOL engagement
Medical Science Liaisons, Andrew Fariello, AstraZeneca, data sharing, technological advancements
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
How to Start Presenting Like a Pro
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary